It can be hard to find biotechs that are investment-grade, especially when you’re not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors’ efforts to make drugs that address the same conditions. And that’s why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.